UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value ELDN Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb ...

Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today reported recent business highlights for its secon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-36620 20-1000967 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value ELDN Nasdaq Global Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Eledon ...

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are g ...

Eledon is currently conducting a Phase 2 trial (BESTOW; NCT05983770), a Phase 1b trial (NCT05027906), and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are grateful ...

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an att ...

Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit. However, there are some penny stocks that, while still containing risk, are much more likely to see real success in the future, potentially leading to significant financial gains for investors. Let's learn about the events and projected successes that showcase these stocks' exciting potential to grow tremendously in the coming years. Source ...

Core Insights - Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart, showing promising safety and efficacy in preventing organ rejection in kidney transplant patients [1][2][3] Group 1: Clinical Trial Results - The overall mean estimated glomerular filtration rate (eGFR) after day 30 post-transplant was reported at 70.5 mL/min/1.73m², with mean eGFR above 60 mL/min/1.73m² at all reported time points [1][2] - Historical studies indicate that standard calcineurin inhibitor-based immunosuppression typically results in mean eGFRs of approximately 50 mL/min/1.73m² during the first year post-transplant, while tegoprubart showed mean eGFRs above 90 mL/min/1.73m² in two participants after one year [2][3] Group 2: Safety Profile - Tegoprubart demonstrated a generally safe and well-tolerated profile, with no cases of hyperglycemia, new onset diabetes, or tremor reported, which are common side effects of standard immunosuppression therapies [3] - Three subjects discontinued the study due to hair loss and fatigue, viral infection, and rejection, but there were no cases of graft loss or death [3] Group 3: Future Developments - Eledon is conducting a Phase 1b trial, a Phase 2 trial (BESTOW), and a long-term safety and efficacy extension study to further evaluate tegoprubart for kidney transplant patients [4][5] - The company anticipates completing enrollment in the Phase 2 BESTOW trial by the end of the year [2]

Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m² at all reported time points after day 30 post-transplant IRVINE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today presented updated data from the Company's ongoing open-label Phase ...

In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price. When it occurs at the bottom of a downtrend, this pattern signals ...